EB-101 Surgical application of RDEB wounds
Phase 3Active 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Epidermolysis Bullosa
Conditions
Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, RDEB
Trial Timeline
Apr 2, 2023 → Sep 30, 2025
NCT ID
NCT05725018About EB-101 Surgical application of RDEB wounds
EB-101 Surgical application of RDEB wounds is a phase 3 stage product being developed by Abeona Therapeutics for Epidermolysis Bullosa. The current trial status is active. This product is registered under clinical trial identifier NCT05725018. Target conditions include Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, RDEB.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05725018 | Phase 3 | Active |
Competing Products
13 competing products in Epidermolysis Bullosa
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Efgartigimod | Argenx | Phase 1/2 | 38 |
| KB803 + Placebo | Krystal Biotech | Phase 3 | 74 |
| Topical beremagene geperpavec + Placebo gel | Krystal Biotech | Phase 1/2 | 38 |
| Topical Beremagene Geperpavec | Krystal Biotech | Phase 3 | 74 |
| Open Label Topical Beremagene Geperpavec (B-VEC) | Krystal Biotech | Phase 3 | 74 |
| SD-101 dermal cream (3%) + SD-101 Dermal Cream (6%) + Vehicle (SD-101 0%) | Amicus Therapeutics | Phase 2 | 49 |
| SD-101-6.0 cream + Placebo (SD-101-0.0) cream | Amicus Therapeutics | Phase 3 | 74 |
| SD-101-6.0 cream | Amicus Therapeutics | Phase 3 | 74 |
| SD-101 dermal cream (6%) | Amicus Therapeutics | Phase 2 | 49 |
| LZRSE-Col7A1 Engineered Autologous Epidermal Sheets | Abeona Therapeutics | Phase 1/2 | 33 |
| EB-101 | Abeona Therapeutics | Phase 3 | 69 |
| VPD-737 | Vyne Therapeutics | Phase 2 | 44 |
| Serlopitant Tablet + Placebo Oral Tablet | Vyne Therapeutics | Phase 2 | 44 |